HMGBiotech is a biotech company that provides reagents, services and ideas to researchers and companies active in the HMGB field.
The only producer of quality-controlled redox variants of HMGB1
Featured news
A recent research has highlighted a groundbreaking discovery concerning the connection between HMGB1 released by mesothelial cells and the development of asbestos-induced mesothelioma.
Worldwide, millions of individuals have been exposed to asbestos, leading to the onset of mesothelioma – a malignancy with unmet therapeutic needs. The research shows how asbestos exposure induces the release of HMGB1 from mesothelial cells: this triggers a plethora of events – TNFα secretion, macrophage accumulation, and atypical mesothelial hyperplasia.
The significance of this study unveils a new role for HMGB1: it emerges not just as a biomarker, but as a potential therapeutic target. Targeting HMGB1 might pave the way for innovative therapies to intervene in the early stages of mesothelioma growth.
HMGBiotech has recently discussed mesothelioma topic, joining CICON 2023 through a poster presentation by Dr. Liam Colley.
CICON is the international reference meeting for scientists, clinicians, regulators, drug developers, and patient advocates.
Liam Colley’s speech about “The role of CXCR4 in Triggering Immunosurveillance in the Malignant Mesothelioma Tumor Environment” reaffirming the focus on how to face mesothelioma and to improve current immunotherapies.
HMGBiotech can provide all the information to help you make an informed decision for your research purposes involving HMGB1.
Discover our HMGB1 proteins and request a quotation
Read the full article about the study: https://www.pnas.org/doi/10.1073/pnas.2307999120
HMGBiotech has joined CICON 2023 through a poster presentation by Dr. Liam Colley.
CICON is the international reference meeting for scientists, clinicians, regulators, drug developers, and patient advocates.
Liam Colley, HMGBiotech’s researcher, gave a speech about “The role of CXCR4 in Triggering Immunosurveillance in the Malignant Mesothelioma Tumor Environment”. During the speech has been highlighted how CXCR4 acts as a hub for anti-tumor immune signaling on malignant mesothelioma cells. CXCR4 is the receptor of CXCL12 chemokine protein: theese proteins create an axis which plays a relevant role in shaping the tumor microenvironment (TME), mainly against dampening immune responses.
The conclusions of the studies about the role of CXCR4 might be exploited to improve current immunotherapies.
HMGBiotech can provide all the information to help you make an informed decision for your research purposes.
Discover our HMGB1 proteins and request a quotation
HMGB1 (High Mobility Group Box 1) isoforms can be used to explore the mechanisms of several disease models.
All proteins are LPS free, so they are suitable for in vitro and in vivo researches.
Fully reduced HMGB1
All the three cysteines are completely reduced. HMGB1 acts as potent chemoattractant for many cells type. Read more…
Disulfide HMGB1
If two cysteines have a disulfide bond. HMGB1 acts as proinflammatory mediator. Read more…
Terminally oxidized HMGB1
The three cysteines are oxidized to sulfonate. HMGB1 is inactive. Read more…
From our LinkedIn profile
Featured Products
About us
HMGBiotech has R&D and production unit within Ospedale San Raffaele, one of the leading research institutes in Italy as per volume and quality of scientific output. Read more about our company…